Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$3 or $13 Eighty/Twenty??
Notice that he doesn’t rail against those that predict Anavex failure/demise with 100% certainty.
Fair and balanced? No time to step on any of those posts.
Good thing you didn’t step in it.
Will there be a pop quiz on this tomorrow?
If you took the time to attack every basher post with equal vigor from people that obviously don’t own a single share of stock, that would really eat up the time needed to manage the other biotechs in the portfolio.
I guess you have to draw the line somewhere.
80/20
20 posts in the last 24 hours and the market wan’t even in session. Today should be a doozy!
“I just don't get why so many would spend their precious time here throwing stones rather than just leaving if they don't like AVXL progression to date. Honestly, the number of naysayers posting multiple times a day is an enigma to me. Suggests much to me about how they value their time.”
Oh don’t you know? The food will be exquisite at the AVXL wake!!!
I just bought doughnuts a bagel and large coffee from Dunkin. Hoping to get a response from Leo to cover it.
When you’ve got no viable explanation, deflecting is all you can do. It’s not your fault. You’re playing it the best you can.
Your dance moves are still woeful.
Any company that spends 80% of their time on customers that make up 20% of their business is destined for failure.
Is that how you run your businesses?
That “Free Money” (shares held at Negative cost) is your money now and helps to offset the losers that frequently come in a portfolio consisting of pre revenue bios. Don’t pretend that an Anavex stock price that withers to zero is pain free.
Most people don’t enjoy going to funerals. A dead stock is worth no one’s time. But you won’t be going anywhere soon to tend to the other sheep in the flock.
“The chances of approval from currently completed and their OLEs is imo quite small - and I would love to be proven wrong...”
Should be easy to answer the question $3 or $13 next. What you say about the trials, the data, the management or lack there of doesn’t necessarily translate to what you believe relative to the stock price. If it did, you would be gone. Nothing to see here for a few years, better things to do and better places to park your money. But it’s like watching the old SNL skit, “The Thing that Wouldn’t Leave”.
I have no investment thesis nor do I own any stock. I am what is commonly known in the industry as a “pompa gentile”. That would be a gentile pumper for those not in the know,
I get paid $12 for every post that distracts Leo’s gaze from the mirror and elicits a response. They believe that is a good gauge of my effectiveness.
$3 or $13 next? Catdaddy got your tongue?
Danish Double Left Foot Shuffle.
My view is that you should stick to singing as your dancing is marginal at best.
So all of this deep diving into the nuance of the science and trial protocol isn’t really intended to let people know what you really think about what matters.
So the science died. You had a low, but higher success probability for Rett than AD and now Rett has withered on the vine. Doc had virtually no chance for either.
So rather than moving on to the other productive assets in an extensive portfolio of pre revenue baby bios you choose to sit here singing dirges in the dark and address each and every post that is counter to the “this song is over” narrative.
I’m sure there is some lame explanation: intrigued by failed science; intrigued by poor CEO stewardship; education of people you openly mock and largely hold disdain for; enhancing your knowledge by reading Kund and Biotech’s postings; overwhelming obsessive enjoyment of sticking a finger in the eye of George, etc.
Your continued presence and need to control the board suggests that there is still money to be made here. Since you have an opinion on everything and comment on seemingly every post, tell the group if you expect a price to first hit the 3’s or the teens in its next movement history.
I’m sure Adam appreciates the help spreading the message. Can’t do it alone.
Should we revisit your last stock price prediction?
Putting in a little OT to tamp down the enthusiasm?
Unfortunate that all those other holdings in a well balanced baby bio portfolio have to go neglected.
But here is a conclusion that has been answered:
“I think I see lower before 6.99.”
Nice call Mr. Bombastic!!!
You can say that again!!
Could have, should have, would have!
Offensive juggernaut putting up 16. All flash, no results.
They averaged 16.6 going into yesterday and put up 16. Looks like same old same old.
I’d look for a better analogy. Try harder!
Steelers
How many points did they score?
Since the Anavex path to approval is truly a Rube Golberg, I’m glad we promoted the right guy into the position. It doesn’t matter how we get there. We just have to get there.
Talking to yourself yet again?
It doesn’t matter what I know. I am just here for the entertainment value and find real enjoyment in being “looked down upon”.
I sold all but one of my shares just in the event the AVXL stock price explodes.
Had he seen everything that Adam F, Doc328 and Investor 2014 had seen prior to signing on?
Not to belabor the point on Dr Jin, but his decision to join Anavex is not too dissimilar to an investment decision in the company. He’s not signing on early in the development pretrial stage. He is jumping in at the most critical point in the history of the company. It is data release and FDA discussion time.
Missling/Anavex had to approach Jin with the premise that last Dec they had the ball 1st and goal at the 2 and took an illegal procedure penalty. They need him to get them over the goal line.
When Jin assesses the state of affairs it is largely:
A) Yes, the data has some hair on it (as you like to say) but I can get you into the end zone. Give me the ball.
B) Even I can’t turn dog shit into gold. Thanks, but no thanks.
The bad news is that Anavex believed it needed Jin to help them into the end zone, meaning there remains some risk.
The good news is that Jin believes he can get them into the end zone and joins the company to take on that effort.
I like our chances.
I just find it difficult to fathom that at this stage he’d be signing on to attend a funeral.
Thanks for the insights.
“Biotech is not for everyone”.
Especially Kun Jin, Ph.D. After having a handful of months to digest what was presented by Anavex at the end of 2022, an employment opportunity with a dead fish was the best he could orchestrate.
I feel that Danish biotech stock prices are rocketing in this market and a well balance Danish baby bio portfolio is absolutely thriving!!!!
Great enough for you to still hold onto your “core” shares!
Free shares? Sure, but a whole lot more valuable a few months ago.
Those Danish Bios will save you!!!!
“No need or reason to read into it any more or less than that.”
What would be the “less” to read into his hiring?
Good strategic move to clutch that 1,000 shares and maintain a license to comment.
And you don’t use it on George because……?